Home
Search
Study Topics
Glossary
|
Study 14 of 2431 for search of: | received on or after 11/14/2008 |
Previous Study | Return to Search Results | Next Study |
Descriptive Information Fields | |||||
---|---|---|---|---|---|
Brief Title † | Varenicline in Bipolar Depressed Patients | ||||
Official Title † | Varenicline for Smoking Cessation in Bipolar Depressed Patients: An Open-Label 12-Week Feasibility Trial | ||||
Brief Summary | Aim 1. To assess the feasibility and acceptability of varenicline among bipolar depressed smokers as determined by our recruitment and retention rates. Hypothesis 1. The abstinence rate for bipolar depressed patients will be 50%. The retention rate for this study will be similar to the Gonzales 2006 study (approximately 75)%. Aim 2. To estimate the 7-day point prevalence abstinence rate at week 12, with open-label varenicline and behavioral intervention among patients with bipolar depression (N=15 with major depression, N=15 with subsyndromal or depressive symptoms). The investigators primary outcome measure is 7-day point prevalence abstinence rate defined by self-report at week 12 confirmed by expired carbon monoxide levels of 10 ppm or less. Hypothesis 2:At final visit, approximately 50% of study completers will meet the primary outcome measure. At study entry, bipolar patients with a major depressive episode, in comparison to subjects with depressive symptoms (i.e. not syndromal episode, less severe) , will have lower abstinence rates.At final visit, bipolar depressed patients who have achieved remission, defined as a Montgomery Asberg Depression Rating Scale (MADRS) <8, will have a higher rate of tobacco abstinence than depressed patients who did not achieve remission (MADRS >/= 8). |
||||
Detailed Description | |||||
Study Phase | |||||
Study Type † | Interventional | ||||
Study Design † | Treatment, Open Label, Single Group Assignment | ||||
Primary Outcome Measure † | The primary outcome measure is a 7-day point prevalence self-report abstinence rate confirmed by expired breath CO < 10 ppm. [ Time Frame: 1 year ] [ Designated as safety issue: No ] | ||||
Secondary Outcome Measure † | A secondary analysis will evaluate abstinence rates based on index mood state (major depression vs. depressive symptoms) and final visit mood state status (remission vs. non-remission). [ Time Frame: 1 year ] [ Designated as safety issue: No ] | ||||
Condition † | Smoking Bipolar Depression |
||||
Intervention † | Drug: Varenicline | ||||
MEDLINE PMIDs | |||||
Links | Mayo Clinic Clinical Trials  | ||||
Recruitment Information Fields | |||||
Recruitment Status † | Not yet recruiting | ||||
Enrollment † | 30 | ||||
Start Date † | January 2009 | ||||
Completion Date | July 2010 | ||||
Eligibility Criteria † | Inclusion Criteria:
Exclusion Criteria:
|
||||
Gender | Both | ||||
Ages | 18 Years to 65 Years | ||||
Accepts Healthy Volunteers | No | ||||
Contacts †† |
|
||||
Location Countries † | United States | ||||
Administrative Information Fields | |||||
NCT ID † | NCT00813800 | ||||
Organization ID | 08-003471 | ||||
Secondary IDs †† | |||||
Study Sponsor † | Mayo Clinic | ||||
Collaborators †† | |||||
Investigators † |
|
||||
Information Provided By | Mayo Clinic | ||||
Verification Date | December 2008 | ||||
First Received Date † | December 22, 2008 | ||||
Last Updated Date | December 22, 2008 |